...
首页> 外文期刊>Cancer gene therapy >Inhibition of angiogenesis in vitro by |[alpha]|v integrin|[ndash]|directed antisense oligonucleotides
【24h】

Inhibition of angiogenesis in vitro by |[alpha]|v integrin|[ndash]|directed antisense oligonucleotides

机译:|α| v整合素| ndash |定向的反义寡核苷酸体外抑制血管生成

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The integrin αvβ3 plays a central role in angiogenesis. In this study, we used antisense oligodeoxyribonucleotides (ONs) directed against the αv subunit of αvβ3 to inhibit integrin expression. Ten ON sequences, which were selected by systematic alignment of computer-predicted secondary structures of αv mRNA, were transfected into human umbilical vein endothelial cells (HUVECs). Following stimulation by PMA, five antisense ONs significantly inhibited αv mRNA and protein expression in activated HUVEC at a concentration of 0.05 μM with complete prevention of PMA-induced αv up-regulation by the most potent antisense ON. Inhibition of αv expression was associated with significant inhibition of migration of HUVEC by 28% and had no effect on proliferation and apoptosis. Moreover, transfection of antisense ON inhibited the formation of tube-like structures of HUVEC in Matrigel by 44%. In a cell culture model of angiogenesis consisting of a co-culture of endothelial cells with fibroblasts, transfection of antisense ONs resulted in an inhibition of tube formation of 61%. In conclusion, αv antisense ONs are potent inhibitors of angiogenesis in vitro. They might, therefore, be a therapeutic alternative to antagonists, which directly bind to αv integrins, and might be useful for the treatment of malignant tumors and hematological malignancies.
机译:整联蛋白αvβ3在血管生成中起重要作用。在这项研究中,我们使用了针对αvβ3的αv亚基的反义寡脱氧核糖核苷酸(ONs)来抑制整联蛋白的表达。通过系统比较计算机预测的αvmRNA二级结构选择的10个ON序列被转染到人脐静脉内皮细胞(HUVEC)中。在受到PMA刺激后,五个反义ON在0.05μM的浓度下显着抑制了活化HUVEC中的αvmRNA和蛋白表达,并通过最有效的反义ON完全阻止了PMA诱导的αv上调。抑制αv表达与抑制HUVEC迁移有28%的相关性,对增殖和凋亡无影响。而且,反义ON的转染将Matrigel中HUVEC的管状结构的形成抑制了44%。在由内皮细胞与成纤维细胞的共培养组成的血管生成细胞培养模型中,反义ON的转染导致对管形成的抑制为61%。总之,αv反义ON是体外血管生成的有效抑制剂。因此,它们可能是与αv整联蛋白直接结合的拮抗剂的治疗替代方法,并可能用于治疗恶性肿瘤和血液系统恶性肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号